NM
KRON

Newtyn Management’s Kronos Bio KRON Stock Holding History

Newtyn Management’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-126,623
Closed -$461K – 82
2022
Q2 		$461K Buy
+126,623
New +$574K 0.09% 71

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Newtyn Management's KRON Position: Q3 2022 in Review

Newtyn Management sold out of Kronos Bio (KRON) in Q3 2022, closing a stake of 126,623 shares — an estimated $461K sold.

Newtyn Management first reported a position in KRON in Q2 2022 and held it in 1 quarter. The position peaked at $461K in Q2 2022. 96 funds tracked by Wall St. Rank hold KRON as of Q3 2022.

  • Newtyn Management reported no remaining Kronos Bio position as of Q3 2022 after selling out during the quarter.
  • Newtyn Management sold 126,623 Kronos Bio shares in Q3 2022, an estimated $461K.
  • Newtyn Management first reported a position in Kronos Bio in Q2 2022 and held it in 1 quarter.
  • Newtyn Management's Kronos Bio position peaked at $461K in Q2 2022.
  • 96 funds tracked by Wall St. Rank held Kronos Bio as of Q3 2022.

Based on Newtyn Management's 13F filing for Q3 2022, filed 14 Nov 2022.